VLP-based bivalent ebola vaccines and methods of making and using same
AssigneeChildren's Hospital Medical Center
InventorsKarnail Singh, Paul Spearman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
Claims8
A method for protecting an individual in need thereof against an Ebola virus species selected from Zaire (EBOV), Sudan (SUDV), Bundibugyo (BDBV), Tai Forest (TAFV), and combinations thereof, comprising administering a virus-like particle (VLP)-based bivalent vaccine composition comprising a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two species of Ebola glycoproteins;
- wherein said at least two species of Ebola glycoproteins are incorporated into a surface of a spherical Gag core;
- wherein said VLP-based bivalent vaccine presents at least two species of Ebola glycoprotein antigens;
- and
- wherein said spherical Gag protein core has a diameter of from about 100 to about 300 nanometers.
Dependencies are inferred from the claim text.